Mindfulness + tVNS for Chronic Kidney Disease
(MIND-CKD Trial)
Trial Summary
The trial requires that you do not take central α-agonists or monoamine oxidase (MAO) inhibitors. If you are on these medications, you would need to stop them to participate.
Research shows that mindfulness-based stress reduction (MBSR) can help reduce stress and improve overall health in people with chronic illnesses, including chronic kidney disease. Additionally, MBSR has been associated with reduced anxiety and improved emotional well-being in various populations.
12345Mindfulness-based stress reduction (MBSR) is generally considered safe for humans and has been widely used in medical settings for over 20 years. Some participants may experience restlessness, physical pain, or difficult emotions during the process, but it is typically well-tolerated.
46789Mindfulness-based stress reduction (MBSR) is unique because it is a non-drug therapy that uses meditation to help manage stress and emotions, which can be beneficial for people with chronic illnesses like chronic kidney disease. Unlike traditional treatments that may focus on medication, MBSR offers a holistic approach that can improve overall well-being and reduce stress-related symptoms.
23468Eligibility Criteria
This trial is for adults with stable chronic kidney disease stages III and IV, without recent heart attacks or strokes, severe CKD, certain nerve conditions, extreme blood pressure levels, heavy substance use, or major surgeries in the past 3 months. Pregnant individuals or those on specific medications like MAO inhibitors are excluded.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants are randomized to 8 weeks of Mindfulness-Based Stress Reduction (MBSR) or a Health Enhancement Program (HEP), with or without transcutaneous vagus nerve stimulation (tVNS).
Follow-up
Participants are monitored for changes in sympathetic nerve activity, blood pressure, heart rate, baroreflex sensitivity, and inflammation.
Participant Groups
Mindfulness-based stress reduction (MBSR) is already approved in United States, European Union, Canada for the following indications:
- Chronic pain
- Anxiety
- Depression
- Stress management
- Chronic pain
- Anxiety
- Depression
- Stress management
- Eating disorders
- Sleep disorders
- Chronic pain
- Anxiety
- Depression
- Stress management